“Extraordinary times require extraordinary measures. The coronavirus crisis prompted us to take extraordinary measures.
For AAT-AD/PD™, the science of finding solutions for patients with Alzheimer’s and Parkinson’s diseases has always been our DNA. Even in difficult times, the science remains our first priority. Exchanging scientific data and sharing novel insights must not wait.
Therefore AAT-AD/PD™ 2020 will not be postponed. For the first time, AAT-AD/PD™ 2020 will be held as an entirely virtual meeting. Instead of meeting in person, we will be meeting virtually over the web. Lectures will be held from remote locations; posters will be shared virtually. Forum discussions and corporate symposia will be webcast online and on time. Exhibitors will be able to meet online to discuss new collaborations.”
The AAT-AD/PD™ scientific program covers the most recent research, clinical trials, and treatments, providing unparalleled insights into neurodegenerative diseases.
The goal of the “Startup Incubator” is to build a highly creative ecosystem of startups and novel participants at the AAT-AD/PD™ conference.
The AD/PD™ Network is a dynamic community of medical professionals who share the common goal of exchanging knowledge about neurodegenerative diseases.